ROCHE/SYNTEX IS DIFFERENT TYPE OF DEAL THAN GENENTECH: SWISS COMPANY FACES TURNAROUND, COST-CUTTING; $5.3 BIL. OFFER CONSUMMATES FOUR-YEAR TORADOL AFFAIR

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".